Comprehensive analysis of the expression levels and prognostic values of PRDX family genes in glioma - PubMed

Comprehensive analysis of the expression levels and prognostic values of PRDX family genes in glioma

Monika Szeliga. Neurochem Int. 2022 Feb.

Abstract

Gliomas are a histologically and molecularly heterogeneous group of neoplasms accounting for 80% of malignant primary brain tumors. Growing evidence suggests that production of reactive oxygen species (ROS) is linked to glioma pathogenesis, although it is still unclear whether it is a cause or an effect of this process. Peroxiredoxins (PRDXs), a family of six antioxidant proteins, may promote or inhibit carcinogenesis, depending on the tumor type and stage. The current knowledge on their expression, regulation and functions in glioma is scarce. In this study, a comprehensive analysis of PRDXs expression in distinct glioma subtypes and non-tumor brain tissues was conducted using gene expression data from The Cancer Genome Atlas (TCGA), REpository for Molecular BRAin NeoplasiaDaTa (REMBRANDT), The Chinese Glioma Atlas (CGGA) and Gene Expression Omnibus (GEO) datasets. The association between gene expression and patient survival was investigated. DNA methylation, mutations, copy number alterations of deregulated PRDXs as well as the correlation between gene expression and tumor-infiltrating immune cells were assessed. The analysis revealed overexpression of PRDX1, PRDX4, and PRDX6 in most histological glioma types compared to the non-tumor tissues, while PRDX2, PRDX3 and PRDX5 expression remained unaltered. The expression of PRDX4 and PRDX6 was higher in mesenchymal than proneural and classical glioma subtypes. Moreover, lower expression of PRDX1, PRDX4 and PRDX6 was observed in tumors with a glioma CpG island methylator phenotype (G-CIMP) compared to non-G-CIMP tumors, as well as in isocitrate dehydrogenase (IDH) mutant and 1p/19q co-deleted gliomas compared to the wild-type counterparts. High expression of PRDX1, PRDX4 or PRDX6 correlated with poor survival of glioma patients. PRDX1 and PRDX6 displayed a positive correlation with different immune cell population in low grade gliomas and, to a lesser extent, in glioblastoma. PRDX1 expression exhibited negative correlation with DNA methylation. These results indicate that high expression of PRDX1, PRDX4 and PRDX6 is associated with poor outcome in gliomas.

Keywords: Gene expression; Glioblastoma; Glioma; Patient survival; Peroxiredoxin.

Similar articles

• Molecular subtypes of glioblastoma are relevant to lower grade glioma.

  Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS. Guan X, et al. PLoS One. 2014 Mar 10;9(3):e91216. doi: 10.1371/journal.pone.0091216. eCollection 2014. PLoS One. 2014. PMID: 24614622 Free PMC article.

• A PRDX1-p38α heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas.

  Wirthschaft P, Bode J, Simon AEM, Hoffmann E, van Laack R, Krüwel T, Dietrich F, Bucher D, Hahn A, Sahm F, Breckwoldt MO, Kurz FT, Hielscher T, Fischer B, Dross N, Ruiz de Almodovar C, von Deimling A, Herold-Mende C, Plass C, Boulant S, Wiestler B, Reifenberger G, Lichter P, Wick W, Tews B. Wirthschaft P, et al. Int J Cancer. 2018 Sep 1;143(5):1176-1187. doi: 10.1002/ijc.31404. Epub 2018 Apr 16. Int J Cancer. 2018. PMID: 29582423

• Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.

  Wiestler B, Capper D, Hovestadt V, Sill M, Jones DT, Hartmann C, Felsberg J, Platten M, Feiden W, Keyvani K, Pfister SM, Wiestler OD, Meyermann R, Reifenberger G, Pietsch T, von Deimling A, Weller M, Wick W. Wiestler B, et al. Neuro Oncol. 2014 Dec;16(12):1630-8. doi: 10.1093/neuonc/nou138. Epub 2014 Jul 15. Neuro Oncol. 2014. PMID: 25028501 Free PMC article.

• Treatment of anaplastic glioma.

  Wick W, Wiestler B, Platten M. Wick W, et al. Cancer Treat Res. 2015;163:89-101. doi: 10.1007/978-3-319-12048-5_6. Cancer Treat Res. 2015. PMID: 25468227 Review.

• Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.

  Malzkorn B, Reifenberger G. Malzkorn B, et al. Pathologe. 2019 Jun;40(Suppl 1):9-17. doi: 10.1007/s00292-019-0581-8. Pathologe. 2019. PMID: 31025086 Review. English.

Cited by

• Current Insights on the Impact of Proteomics in Respiratory Allergies.

  Vizuet-de-Rueda JC, Montero-Vargas JM, Galván-Morales MÁ, Porras-Gutiérrez-de-Velasco R, Teran LM. Vizuet-de-Rueda JC, et al. Int J Mol Sci. 2022 May 20;23(10):5703. doi: 10.3390/ijms23105703. Int J Mol Sci. 2022. PMID: 35628512 Free PMC article. Review.

• Unveiling the Significance of Peroxiredoxin 6 in Central Nervous System Disorders.

  Xue M, Huang X, Zhu T, Zhang L, Yang H, Shen Y, Feng L. Xue M, et al. Antioxidants (Basel). 2024 Apr 10;13(4):449. doi: 10.3390/antiox13040449. Antioxidants (Basel). 2024. PMID: 38671897 Free PMC article. Review.

• Conoidin A, a Covalent Inhibitor of Peroxiredoxin 2, Reduces Growth of Glioblastoma Cells by Triggering ROS Production.

  Szeliga M, Rola R. Szeliga M, et al. Cells. 2023 Jul 26;12(15):1934. doi: 10.3390/cells12151934. Cells. 2023. PMID: 37566013 Free PMC article.

• Targeting reactive oxygen species and fat acid oxidation for the modulation of tumor-associated macrophages: a narrative review.

  Teng Y, Xu L, Li W, Liu P, Tian L, Liu M. Teng Y, et al. Front Immunol. 2023 Jul 21;14:1224443. doi: 10.3389/fimmu.2023.1224443. eCollection 2023. Front Immunol. 2023. PMID: 37545527 Free PMC article. Review.

• Sp1-Mediated Prdx6 Upregulation Leads to Clasmatodendrosis by Increasing Its aiPLA2 Activity in the CA1 Astrocytes in Chronic Epilepsy Rats.

  Kim JE, Lee DS, Kang TC. Kim JE, et al. Antioxidants (Basel). 2022 Sep 23;11(10):1883. doi: 10.3390/antiox11101883. Antioxidants (Basel). 2022. PMID: 36290607 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal